• 1. Department of Hematology / Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;
  • 2. West China School of Medicine, Sichuan University, Chengdu, Sichuan 610041, P. R. China;
  • 3. Department of Hematology, Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu University, Chengdu, Sichuan 610081, P. R. China;
ZHANG Li, Email: drzhangli2014@sina.com
Export PDF Favorites Scan Get Citation

Regulatory B cells (Bregs) are a subset of B cells with immunomodulatory effects. The study of Bregs began with a variety of animal models of immune diseases. Studies in patients with autoimmune diseases have further clarified that Bregs are a group of immune cells that secrete inhibitory cytokines such as interleukin-10. Abnormal functions and numbers of Bregs have been found in a variety of autoimmune diseases. The study of the negative immune regulatory network involving Bregs is expected to provide new therapeutic ideas for diseases such as immune diseases, cancer, infection and inflammation. Starting from the discovery and immune regulation mechanism of Bregs, this paper focuses on its regulatory mechanism and clinical research value in the occurrence and development of autoimmune diseases, tumors, infectious diseases and inflammation.

Citation: CUI Jian, ZOU Zhongqing, ZHANG Li. Research progress of regulatory B cells in diseases. West China Medical Journal, 2022, 37(4): 632-636. doi: 10.7507/1002-0179.202005018 Copy

  • Previous Article

    Study on the pathogenesis of monoclonal gammopathy of renal significance
  • Next Article

    经导管二尖瓣缘对缘修复术救治急性心肌梗死并发二尖瓣乳头肌断裂一例